Erik H Knelson
Overview
Explore the profile of Erik H Knelson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
733
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murayama T, Mahadevan N, Meador C, Ivanova E, Pan Y, Knelson E, et al.
Cancer Res Commun
. 2024 Aug;
4(9):2399-2414.
PMID: 39177280
Small-cell lung cancer (SCLC) is the most lethal type of lung cancer. Paradoxically, this tumor displays an initial exquisite response to chemotherapy; however, at relapse, the tumor is highly resistant...
2.
Kitajima S, Tani T, Springer B, Campisi M, Osaki T, Haratani K, et al.
Cancer Cell
. 2022 Sep;
40(10):1128-1144.e8.
PMID: 36150391
KRAS-LKB1 (KL) mutant lung cancers silence STING owing to intrinsic mitochondrial dysfunction, resulting in T cell exclusion and resistance to programmed cell death (ligand) 1 (PD-[L]1) blockade. Here we discover...
3.
Yoshida R, Saigi M, Tani T, Springer B, Shibata H, Kitajima S, et al.
Cancer Res
. 2022 Sep;
82(21):4079-4092.
PMID: 36066413
Significance: MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment.
4.
Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies
Campisi M, Shelton S, Chen M, Kamm R, Barbie D, Knelson E
Cancers (Basel)
. 2022 Jul;
14(15).
PMID: 35892819
Cell therapies, including adoptive immune cell therapies and genetically engineered chimeric antigen receptor (CAR) T or NK cells, have shown promise in treating hematologic malignancies. Yet, immune cell infiltration and...
5.
Berger G, Knelson E, Jimenez-Macias J, Nowicki M, Han S, Panagioti E, et al.
Proc Natl Acad Sci U S A
. 2022 Jul;
119(28):e2111003119.
PMID: 35787058
Immunotherapy has had a tremendous impact on cancer treatment in the past decade, with hitherto unseen responses at advanced and metastatic stages of the disease. However, the aggressive brain tumor...
6.
Knelson E, Ivanova E, Tarannum M, Campisi M, Lizotte P, Booker M, et al.
Cancer Immunol Res
. 2022 Jun;
10(8):947-961.
PMID: 35678717
Activation of the stimulator of interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding of the mechanism of action of STING...
7.
Bar-Sagi D, Knelson E, Sequist L
Nat Cancer
. 2022 Feb;
1(1):25-27.
PMID: 35121842
No abstract available.
8.
Hong D, Knelson E, Li Y, Durmaz Y, Gao W, Walton E, et al.
Cancer Res
. 2021 Nov;
82(2):248-263.
PMID: 34810201
Neuroendocrine to nonneuroendocrine plasticity supports small cell lung cancer (SCLC) tumorigenesis and promotes immunogenicity. Approximately 20% to 25% of SCLCs harbor loss-of-function (LOF) mutations. Previous studies demonstrated that NOTCH functions...
9.
Gupta S, Dawood H, Giantini Larsen A, Fandino L, Knelson E, Smith T, et al.
Front Oncol
. 2021 May;
11:662943.
PMID: 34026641
Introduction: Brain metastases are the most common brain tumors in adults, whose management remains nuanced. Improved understanding of risk factors for surgical complications and mortality may guide treatment decisions. Methods:...
10.
Mahadevan N, Knelson E, Wolff J, Vajdi A, Saigi M, Campisi M, et al.
Cancer Discov
. 2021 Mar;
11(8):1952-1969.
PMID: 33707236
Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we...